Buprenorphine controlled release - Serina Therapeutics
Alternative Names: SER-227Latest Information Update: 04 Aug 2023
At a glance
- Originator Serina Therapeutics
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Opioid-related disorders; Postoperative pain
Most Recent Events
- 04 Aug 2023 Chemical structure information added
- 23 Apr 2023 Preclinical trials in Opioid-related disorders in USA (Parenteral) (Serina Therapeutics pipeline; April 2023)
- 23 Apr 2023 Preclinical trials in Postoperative pain in USA (Parenteral) (Serina Therapeutics pipeline; April 2023)